|2.40||+0.1300||+5.73%||Vol 105.18K||1Y Perf -60.45%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.04 1.67%|
|Target Price||15.71||Analyst Rating||Strong Buy 1.00|
|Potential %||554.58||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||16.21||Earnings Rating||—|
|Market Cap||92.62M||Earnings Date||10th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.70|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||179.42K|
|Avg. Monthly Volume||176.13K|
|Avg. Quarterly Volume||290.63K|
Atreca Inc. (NASDAQ: BCEL) stock closed at 2.4 per share at the end of the most recent trading day (a 5.73% change compared to the prior day closing price) with a volume of 105.18K shares and market capitalization of 92.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 128 people. Atreca Inc. CEO is John A. Orwin.
The one-year performance of Atreca Inc. stock is -60.45%, while year-to-date (YTD) performance is -20.79%. BCEL stock has a five-year performance of %. Its 52-week range is between 1.51 and 7, which gives BCEL stock a 52-week price range ratio of 16.21%
Atreca Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.05%, a ROC of -50.63% and a ROE of -62.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Atreca Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. Atreca Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Atreca Inc. is Strong Buy (1), with a target price of $15.71, which is +554.58% compared to the current price. The earnings rating for Atreca Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Atreca Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Atreca Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.93, ATR14 : 0.22, CCI20 : 101.53, Chaikin Money Flow : 0.05, MACD : 0.08, Money Flow Index : 61.95, ROC : 25.00, RSI : 48.27, STOCH (14,3) : 72.22, STOCH RSI : 0.75, UO : 58.40, Williams %R : -27.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Atreca Inc. in the last 12-months were: Tito A. Serafini (Sold 75 000 shares of value $377 807 )
Tue, 09 Aug 2022 00:40 GMT Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Atreca (BCEL) and CSL (OtherCMXHF)- TipRanks. All rights reserved.
Sun, 06 Mar 2022 14:10 GMT Atreca (BCEL) Gets a Buy Rating from Stifel Nicolaus- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.